Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
MindMed ($MMED | $MDNMD) provided positive results from their Phase II clinical trial focused on LSD as a potential treatment for anxiety disorders. The data demonstrated significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression. Press Release
Wesana Health Holdings ($WESA) successfully completed their Pre-IND meeting with the FDA. Wesana Health is expanding their lead indication for SANA-013 to Major Depressive Disorder and exploring other complementary orphan indications. Press Release
Cybin ($CYBN) announced pilot results from a Cybin-sponsored feasibility study evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure cortical hemodynamics while experiencing an altered state of consciousness. Preliminary data from the study suggested that ketamine-induced changes in functional connectivity persisted for several days after administration. Press Release
Field Trip Health ($FTRP) launched Field Trip at Home with Nue Life, a leader in mental wellness telehealth and at-home ketamine treatments. Field Trip at Home is an advanced wellness platform for personalized, at-home psychedelic care. Press Release
Novamind ($NM | $NVMDF) has been selected to host a clinical trial for the acute treatment of social anxiety disorder. The Phase II randomized study is sponsored by Bionomics Ltd and will examine the safety and efficacy of their propriety drug candidate. Press Release
Wellbeing Digital Sciences ($MEDI) became a founding sponsor of the Women in Psychedelics Network. WIP was created to bring women together in the psychedelic industry and build a community based on education, support, growth, and experience. Press Release
Optimi Health ($OPTI | $OPTHF) completed a planned expansion of the on-site analytical laboratory at their British Columbia facility. The state-of-the-art indoor growing facilities is dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Press Release
COMPASS Pathways ($CMPS) will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults. Press Release
Nova Mentis Life Science ($NOVA | $NMLSF) appointed Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy John Molinaro to their Scientific Advisory Board. Press Release